Innate Pharma (IPHA) Restructuring Costs (2022)

Innate Pharma's (IPHA) quarterly Restructuring Costs came in at -$41.8 million in Q4 2022.

Innate Pharma (IPHA) Restructuring Costs (2022) Analysis & Trends

Innate Pharma (IPHA) has 1 years of Restructuring Costs data on file, last reported at -$41.8 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.81 Bn	130.96 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.07 Bn	78.08 Bn	3.93 Bn
3	Argenx Se	65.47 Bn	60.29 Bn	1.37 Bn
4	Moderna	55.64 Bn	50.50 Bn	52.00 Mn
5	BeOne Medicines	41.99 Bn	36.89 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.68 Bn	28.37 Bn	992.69 Mn
7	BioNTech SE	27.69 Bn	9.29 Bn	668.28 Mn
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
9	Royalty Pharma	27.36 Bn	26.52 Bn	-
10	Innate Pharma	199.79 Mn	199.79 Mn	-

Download Data

Date	Value
Dec 31, 2022	-41.83 Mn